Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
PYC
vs
S
S&P/ASX 300
PYC
Over the past 12 months, PYC has significantly outperformed S&P/ASX 300, delivering a return of +70% compared to S&P/ASX 300's 3% drop.
Stocks Performance
PYC vs S&P/ASX 300
Performance Gap
PYC vs S&P/ASX 300
Performance By Year
PYC vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PYC Therapeutics Ltd
Glance View
PYC Therapeutics is a biotechnology company that develops RNA-based medicines for inherited diseases. Its core idea is to design short RNA molecules that help cells make the right protein when a gene is not working properly. The company is focused on rare disorders with clear genetic causes, where fixing the underlying RNA problem may address the disease itself rather than just the symptoms. The company does not sell consumer products. It earns value by creating drug candidates and advancing them through laboratory and clinical development, often through partnerships with larger drug companies or through future licensing and commercialization deals. In this model, PYC acts as an early-stage drug developer: it identifies disease targets, designs the therapy, tests it, and seeks partners or buyers once a program is ready for broader development. What makes PYC different is its focus on splice-modifying RNA medicines, a more precise approach than many traditional drugs. Instead of trying to replace a missing protein or broadly treat symptoms, its platform aims to correct how the body reads a faulty gene message. That gives the company a specialized role in the drug-development chain, especially in rare genetic diseases where targeted treatments can be valuable.